Who Paid My Doc
Halaven
Drug Oncology
NDC 62856-389-01
General payments
$708,051
Research payments
$6,437,724
Through program year 2025, $708,051 in general payments and $6,437,724 in research payments were reported against Halaven (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
13 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $68 | 1 |
| 2025 | Research | $191,763 | 8 |
| 2024 | Research | $10,281 | 2 |
| 2023 | General | $36,999 | 10 |
| 2023 | Research | $49,641 | 9 |
| 2022 | General | $36,035 | 471 |
| 2022 | Research | $239,151 | 13 |
| 2021 | General | $86,461 | 378 |
| 2021 | Research | $974,288 | 140 |
| 2020 | General | $180,125 | 778 |
| 2020 | Research | $534,238 | 318 |
| 2019 | General | $368,364 | 1,350 |
| 2019 | Research | $4,438,362 | 2,228 |
Breakdown
Each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
2,988 general · 2,718 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.